Corsair Pharma has developed a proprietary transdermal patch intended to provide consistent blood levels of treprostinil, a drug currently administered via a 24/7 infusion pump (sub-cutaneous or intra-venous, see this link for more details), by delivering an inactive prodrug, which crosses the skin, enters the blood, and converts rapidly to treprostinil in the liver. Since the prodrug is inactive, the patch could mitigate the issues of infusion site pain or discomfort that may occur with sub-cutaneous delivery.
Corsair intends to initiate Phase 1 clinical trial to evaluate pharmacokinetics and safety/tolerability of the candidate product in the second half of 2024.
To be followed.
Source: https://www.corsairpharma.com/